Pruritus in Atopic Dermatitis Market: With the Rise in Patient Pool, Drug Development to Progress Rapidly

Published on : Mar 14, 2018

Albany, New York, March 14, 2018: Prusitus in Atopic Dermatitis can be explained as itching caused in the cases of atopic dermatitis. Atoapic dermatitis is a condition where mostly children or people with a family history of this problem develop rashes on different areas of body, mostly arms and behind the knees. A new research report is based on epidemiology of Pruritus in Atopic Dermatitis. The report is titled ‘Pruritus in Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2027.’

Pruritus in Atopic Dermatitis Market: Overview

This comprehensive research report covers a wide area of global pruritus in atopic dermatitis market. It highlights therapies that have a large market share, forecast for upcoming market trends and its impact. There is also an analysis of the population worldwide, suffering from pruritus in atopic dermatitis and its severity. According to the report, population prevalent of pruritus in atopic dermatitis was estimated to be over 20 Million in 2016 and is expected to keep rising in the coming years.

To combat the problem of people are facing, many drug companies are coming up with new drug discoveries, that are still in the pipeline at phase III or phase II. Some of these upcoming therapies of pruritus in atopic dermatitis are NST-141 (Nippon Shinyaku), Nemolizumab (Galderma Pharma), ZPL-389 (Novartis), Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals) etc. The report also presents an examination of existing drugs in the market, helping readers get an insight to the market of each drug, patent details, clinical trials, their advantages and disadvantages. There are many drivers of the market that, even on a macroeconomic level, that is triggering the growth for many drug manufacturers in pruritus in atopic dermatitis market.

Pruritus in Atopic Dermatitis Market: Market Segmentation

To help readers in easy understanding of global pruritus in atopic dermatitis market is segmented into segments based on different parameters. This includes segmentation based on severity of pruritus, burden and region. The key regions global pruritus in atopic dermatitis market is bifurcated in comprises US, Europe, UK and Japan. All these regions are critically analysed in terms of product developments taking place, drugs that are witnessing high sales, companies that are leading in the region, trends prevailing in the region’s market, technological advancements taking place, patient pool, disease types witnessed, progress stages of research and development in process.

Pruritus in Atopic Dermatitis Market: Key Players

Many companies are looking for ways to capitalize on the growing demand for drugs in global pruritus in atopic dermatitis market. This research report exhibits a detailed profile of all the companies that have a huge market share and are rapidly growing. Some of the key players mentioned in the report are Novartis, Nippon, Shinyaku, DS Biopharma, Asimadoline, Tioga Pharmaceuticals, GlaxoSmithKline, Dermata Therapeutics, Sienna Biopharmaceutical, Roivant Sciences, Otsuka Pharmaceutical etc. This section helps the readers get a competitive edge in the market by understanding the strategies companies have adopted over the years and are planning to implement in the coming years.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top